Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited.

Article Details

Citation

Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M

Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited.

J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19.

PubMed ID
18713951 [ View in PubMed
]
Abstract

Angiotensin-converting enzyme (ACE) inhibitors are often regarded as substrates for the H+/peptide transporters (PEPT)1 and PEPT2. Even though the conclusions drawn from published data are quite inconsistent, in most review articles PEPT1 is claimed to mediate the intestinal absorption of ACE inhibitors and thus to determine their oral availability. We systematically investigated the interaction of a series of ACE inhibitors with PEPT1 and PEPT2. First, we studied the effect of 14 ACE inhibitors including new drugs on the uptake of the dipeptide [14C]glycylsarcosine into human intestinal Caco-2 cells constitutively expressing PEPT1 and rat renal SKPT cells expressing PEPT2. In a second approach, the interaction of ACE inhibitors with heterologously expressed human PEPT1 and PEPT2 was determined. In both assay systems, zofenopril and fosinopril were found to have very high affinity for binding to peptide transporters. Medium to low affinity for transporter interaction was found for benazepril, quinapril, trandolapril, spirapril, cilazapril, ramipril, moexipril, quinaprilat, and perindopril. For enalapril, lisinopril, and captopril, very weak affinity or lack of interaction was found. Transport currents of PEPT1 and PEPT2 expressed in Xenopus laevis oocytes were recorded by the two-electrode voltage-clamp technique. Statistically significant, but very low currents were only observed for lisinopril, enalapril, quinapril, and benazepril at PEPT1 and for spirapril at PEPT2. For the other ACE inhibitors, electrogenic transport activity was extremely low or not measurable at all. The present results suggest that peptide transporters do not control intestinal absorption and renal reabsorption of ACE inhibitors.

DrugBank Data that Cites this Article

Drug Transporters
DrugTransporterKindOrganismPharmacological ActionActions
BenazeprilSolute carrier family 15 member 1ProteinHumans
Unknown
Substrate
Details
BenazeprilSolute carrier family 15 member 2ProteinHumans
Unknown
Substrate
Details
CilazaprilSolute carrier family 15 member 1ProteinHumans
Unknown
Substrate
Details
CilazaprilSolute carrier family 15 member 2ProteinHumans
Unknown
Substrate
Details
FosinoprilSolute carrier family 15 member 1ProteinHumans
Unknown
Substrate
Details
FosinoprilSolute carrier family 15 member 2ProteinHumans
Unknown
Substrate
Details
LisinoprilSolute carrier family 15 member 1ProteinHumans
Unknown
Substrate
Inhibitor
Details
LisinoprilSolute carrier family 15 member 2ProteinHumans
Unknown
Substrate
Details
MoexiprilSolute carrier family 15 member 1ProteinHumans
Unknown
Substrate
Details
MoexiprilSolute carrier family 15 member 2ProteinHumans
Unknown
Substrate
Details
PerindoprilSolute carrier family 15 member 1ProteinHumans
Unknown
Substrate
Details
PerindoprilSolute carrier family 15 member 2ProteinHumans
Unknown
Substrate
Details
QuinaprilSolute carrier family 15 member 1ProteinHumans
Unknown
Substrate
Details
QuinaprilSolute carrier family 15 member 2ProteinHumans
Unknown
Substrate
Details
RamiprilSolute carrier family 15 member 1ProteinHumans
Unknown
Substrate
Details
RamiprilSolute carrier family 15 member 2ProteinHumans
Unknown
Substrate
Details
SpiraprilSolute carrier family 15 member 1ProteinHumans
Unknown
Substrate
Details
SpiraprilSolute carrier family 15 member 2ProteinHumans
Unknown
Substrate
Details
TrandolaprilSolute carrier family 15 member 1ProteinHumans
Unknown
Substrate
Details
TrandolaprilSolute carrier family 15 member 2ProteinHumans
Unknown
Substrate
Details